Toca 511 & Toca FC

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Toca 511 & Toca FC

Toca 511, the key novel component of Tocagen's [1] first Product Candidate (Toca 511 & Toca FC),[2] was developed using Controlled Active Gene Transfer (CAGT) technology.[3] The CAGT platform is a Retroviral Replicating Vector (RRV) that carries the complete complement of viral genes (gag, pol, env) which allow viral replication and subsequent delivery of a therapeutic gene throughout a tumor.[4]

Toca 511 is intended to be used in combination with Toca FC. Toca FC is a novel extended-release tablet containing 5-FC (flucytosine).

Toca 511 & Toca FC is being investigated in a Phase I/II clinical trial for the treatment of recurrent high grade glioma (HGG) brain cancer, including glioblastoma multiforme (GBM).[5]

References[edit]

  1. ^ "Tocagen Inc.". Tocagen.com. 2012-04-08. Retrieved 2012-08-04. 
  2. ^ "Products". Tocagen.com. 2012-04-08. Retrieved 2012-08-04. 
  3. ^ "Technology". Tocagen.com. 2012-04-08. Retrieved 2012-08-04. 
  4. ^ Molecular Therapy (2005-11-01). "Molecular Therapy - Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma". Nature.com. Retrieved 2012-08-04. 
  5. ^ "Clinical Trials". Tocagen.com. 2012-04-08. Retrieved 2012-08-04. 

External links[edit]